Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
Nurix (NRIX) PT Raised to $34 at Stifel
October 14, 2024 8:33 AM EDT(Updated - October 14, 2024 8:34 AM EDT)
Stifel analyst Stephen Willey raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $30.00) while maintaining a Buy rating.
The analyst commented: "We like implied risk/reward into the anticipated update of P1/1b NX-5948 data... More
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
October 14, 2024 7:36 AM EDTPiper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $35.00 price target on Nurix (NASDAQ: NRIX).
The analyst commented, "NRIX reported 3Q24 earnings and provided a pipeline update. Most importantly, development of NX-5948 remains on track with two Phase Ia updates expected... More
Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS
October 14, 2024 3:50 AM EDTNurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($0.67), in-line with the analyst estimate of ($0.67). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $14.98 million.
For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.
... MoreJefferies Starts Nurix (NRIX) at Buy
October 11, 2024 5:25 AM EDTJefferies analyst Roger Song initiates coverage on Nurix (NASDAQ: NRIX) with a Buy rating and a price target of $41.00.
The analyst said: "NRIX focuses on targeted protein modulation for cancer and I&I. Lead '5948 (BTK degrader) aims to better address broad BTK... More
